1 / 101

The Saudi Initiative for Asthma

The Saudi Initiative for Asthma. On behalf of the SINA group Mohamed S. Al-Moamary, FRCP (Edin) FCCP King Abdulaziz Medical City-Riyadh King Saud bin Abdulaziz Uinversity for Health Scinces. June 2010. Asthma Diagnosis & Management . Enter presenter name Enter the presenter’s institute .

herve
Download Presentation

The Saudi Initiative for Asthma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Saudi Initiative for Asthma On behalf of the SINA group Mohamed S. Al-Moamary, FRCP (Edin) FCCP King Abdulaziz Medical City-Riyadh King Saud bin Abdulaziz Uinversity for Health Scinces June 2010

  2. Asthma Diagnosis & Management Enter presenter name Enter the presenter’s institute

  3. What is SINA? • SINA is developed by a task force originated from the Saudi Initiative for Asthma Group under the umbrella of the Saudi Thoracic Society • SINA is a practical approach for a comprehensive management of asthma in adults and children and when to refer to a specialist. • International recommendations were customized to the local setting for asthma diagnosis and management • Directed to HCW dealing with asthma who are not specialists in the field.

  4. Purpose of SINA • To provide a document that is easy to follow, simple to understand yet totally updated and carefully prepared for use by non-asthma specialist including primary care doctors and general practice physicians

  5. Where do you find SINA? • The SINA guideline was published in the Annals of Thoracic Medicine: Al-Moamary MS, Al-Hajjaj MS, Idrees MM, Zeitouni MO, Alanezi MO, Al-Jahdali HH, Al Dabbagh M. The Saudi Initiative for asthma. Ann Thorac Med 2009;4:216-33 (www.thoracicmedicine.org): • The SINA guidelines booklet is available at: www.sinagroup.org

  6. Saudi Thoracic Society commitment • The STS is committed to improve the care of asthma by a long term plan: • Periodic scientific meetings • Annual asthma meeting (since 2001) • Frequent asthma courses • Educational brochures • Publishing new and updated asthma guidelines

  7. SINA Task Force • Mohamed S. Al-Moamary (Head), College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh • Mohamed S. Al-Hajjaj, College of Medicine, King Saud University, Riyadh • Majdy M. Idrees, Military Hospital, Riyadh • Mohamed O. Zeitouni, King Faisal Specialist Hospital and Research Center, Riyadh • Mohammed O. Alanezi, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh • Hamdan H. Al-Jahdali, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh • Maha M. Al Dabbagh, King Fahd Armed Forces Hospital, Jeddah

  8. Acknowledgment The Saudi Initiative for Asthma group would like to thank the following reviewers : • Prof. Eric Bateman from the University of Cape Town Lung Institute, Cape Town, South Africa • Prof. J. Mark FitzGerald from the University of British Columbia, Vancouver, BC, Canada • Prof. Ronald Olivenstein from the Meakins-Christie Laboratories and the Montreal Chest Research Institute, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.

  9. SINA Documents • Published manuscript • Booklet • Electronic version • Slides kit • Flyers • Website: www.sinagroup.org

  10. Sections of SINA • Epidemiology • Pathophysiology • Diagnosis • Medications • Approach to Management • Treatment Steps • Special Situations • Acute Asthma

  11. Prevalence • Prevalence of asthma has increased between 1986 – 1995 Alfrayyah et al. Ann Allergy Asthma Immunol 2001;86:292–296

  12. Burden of Asthma • Asthma is among the most common chronic illnesses in Saudi Arabia • 53% had missed school or work (AIRKSA-2007) • 35% attempted Unconventional therapy (Al Moamary, ATM 2008) • 46% were controlled in Riyadh (AIRKSA-2007) • 36% were controlled in 5 tertiary care centers in Riyadh (Aljahdali SMJ-2008) • 48% were controlled in one center (Al Moamary, ATM 2008)

  13. AIRKSA report (Ministry of Health) • 78 % of adults & 84% of kids reported acute asthma over 12 months (AIRKSA) • 54 % of adults & 80% of kids reported ER over 12 months (AIRKSA) • 45-68% of adults & 37-56% of kids reported limitation of activity over 12 months (AIRKSA) • 76 % of adults & 78% of kids never had spirometry(AIRKSA)

  14. Pattern of asthma treatment Ann Thorac Med 2006;1:20-5

  15. Pathology of Asthma Inflammation Airway Hyper-responsiveness Airway Obstruction Symptoms of Asthma

  16. Pathophysiology

  17. Inflammation  Remodeling • Inflammation • Airway Hypersecretion • Subepithelial fibrosis • Angiogenesis

  18. Diagnosis - History • Episodic attacks: • Cough • Breathlessness • Wheezing • Nocturnal symptoms • Patient could be asymptomatic between attacks • co-existent conditions: GERD, rhinosinusitis.

  19. Relevant Questions

  20. Physical Examination • Normal between attacks • Bilateral expiratory wheezing • Examination of the upper airways • Other allergic manifestations: e.g., atopic dermatitis/eczema • Consider alternative Dx when there is localized wheeze, crackles, stridor, clubbing

  21. Investigations • Measurements of lung function: • Spirometry • Peak expiratory flow (PEF) • Normal Spirometry does not role out asthma • Spirometry is superior to PEF

  22. Bronchodilator response

  23. Clinical Assessment • Measurements of allergic status to identify risk factors (if indicated) • Chest X-ray is not routinely recommended • Routine blood tests are not routinely recommended • IgE measurement is indicated in severe cases

  24. Level of Control: • Control: 20-24 • Partial control: 16-19 • Uncontrolled: < 16

  25. Differential Diagnosis • Upper airway diseases • Allergic rhinitis and sinusitis • Obstructions involving large airways • Foreign body in trachea or bronchus • Vocal cord dysfunction • Vascular rings or laryngeal webs • Laryngotracheomalacia, tracheal stenosis, or bronchostenosis • Enlarged lymph nodes or tumor • Obstructions involving small airways • Viral bronchiolitis or obliterative bronchiolitis • Cystic fibrosis • Bronchopulmonary dysplasia • Heart disease • Other causes • Recurrent cough not due to asthma • Aspiration from swallowing mechanism dysfunction or GERD

  26. Differential Diagnosis • COPD (e.g., chronic bronchitis or emphysema) • Congestive heart failure • Pulmonary embolism • Mechanical obstruction of the airways (benign and malignant tumors) • Pulmonary infiltration with eosinophilia • Cough secondary to drugs (e.g., angiotensin-converting enzyme (ACE) inhibitors) • Vocal cord dysfunction

  27. Asthma in children < 5 years • The diagnosis is challenging • Asthma must be distinguished from other causes of persistent and recurrent wheezing • The earlier the onset of a wheeze, the better the prognosis • A family history of atopy and asthma and maternal atopy are strongly associated with persistent childhood asthma

  28. Asthma in children < 5 years • Three categories of wheezing: • Transient early wheezing: • It outgrown in the first three years • It associated with prematurity and parental smoking. • Persistent early-onset wheezing: • Symptoms continue beyond the age of six • Associated with acute viral respiratory infections and have no evidence of atopy • Late-onset wheezing/asthma: • Symptoms persist into childhood and adult life. • Atopic background, often with eczema

  29. Asthma in children < 5 years • No tests can diagnose asthma with certainty. • Lung function testing is not very helpful • CXR may help to exclude structural abnormalities of the airway. • A trial of treatment with short-acting bronchodilators and inhaled corticosteroids (ICS) for at least 8 to 12 weeks may provide some guidance as to the presence of asthma.

  30. Management

  31. Patient/Dr Partnership • Enhance the chance of disease control • Agreed goals of management • Guided self-management plan

  32. Asthma Education

  33. Drugs: Poor technique of inhaler devices. Regimen with multiple drugs. Occurrence of Side effects from the drugs. Cost of medications. Non-drugs Lack of knowledge about asthma. Lack of partnership in the management. Inappropriate expectations. Underestimation of severity. Cultural issues. Non-Adherence

  34. Precipitating Factors • Indoor Allergens and Air Pollutants • Outdoor Allergens • Occupational Exposure • Food and Drugs

  35. Self-management plan لكل مريض خطة علاجية ذاتية خاصة به توضع تحت إشراف الطبيب المختص حسب حالته

  36. Asthma Medications • Controllersare medications taken daily on a long-term basis to keep asthma under clinical control chiefly through their anti-inflammatory effects. • Relieversare medications used on an as-needed basis that act quickly to reverse • bronchoconstriction and relieve symptoms.

  37. Controller Medications • Inhaled glucocorticosteroids • Leukotriene modifiers • Long-acting inhaled B2-agonists • Theophylline • Anti-IgE • Systemic glucocorticosteroids

  38. Inhaled Corticosteroids • The most effective antiinflammatory medications for the treatment of asthma • Benefits of ICS: • Reduce symptoms: • improve quality of life • improve lung function • decrease airway hyperresponsiveness • control airway inflammation • reduce frequency and severity of exacerbations, and reduce mortality.

  39. Inhaled Corticosteroids • When ICS discontinued, deterioration of clinical control follows within weeks to months in most patients • Most of the benefits from ICS are achieved in adults at relatively low doses • Increasing to higher doses may provide further benefits in terms of asthma control but increases the risk of side effects • Tobacco smoking reduces the responsiveness to ICS

  40. Inhaled Corticosteroids • To reach control, add-on therapy with another class of controller is preferred to increasing the dose of ICS • ICS are generally safe and well-tolerated • Though low-medium dose of ICS may affect growth velocity, this effect is clinically insignificant and may be reversible.

  41. Inhaled Corticosteroids • Local adverse effects: • oropharyngeal candidiasis • Dysphonia – may be e reduced by using MDI + spacer devices and mouth washing • Systemic side effects are occasionally reported with high doses and long-term treatment

  42. Inhaled Corticosteroids

  43. Leukotriene modifiers (LTRA) • LTRA reduce airway inflammation and improve asthma symptoms and lung function but with a less consistent effect on exacerbations, especially when compared to ICS. • Alternative treatment to ICS for patients with mild asthma, especially in those who have clinical rhinitis • Some patients with aspirin-sensitive asthma respond well to the LTRA

  44. Leukotriene modifiers (LTRA) • Available as Montelokast in Saudi Arabia • Their effects are generally less than that of low dose ICS • When added to ICS, LTRA may reduce the dose of ICS required by patients with uncontrolled asthma, and may improve asthma control • LTRA are generally well-tolerated. There is no clinical data to support their use under the age of six months.

  45. LABA • LABA: (formoterol and salmeterol) • Should not be used as monotherapy • Combination with ICS lead to: • improves symptoms • decreases nocturnal asthma • improves lung function • decreases the use rapid-onset inhaled B2-agonists • reduces the number of exacerbations • achieves clinical control of asthma in more patients, more rapidly, and at a lower dose of ICS

  46. Combination devices • Sympicort turbohaler: • Budesonide/Formeterol: 160/4.5 • Seretide: • Fluticasone/Salmeterol • Evohaler: 50/8 125/8 250/8 • Diskus: 100/16 250/16 500/16

  47. Theophylline • Weak bronchodilator with modest anti-inflammatory properties. • It may provide benefit as add-on therapy in patients who do not achieve control on ICS alone • Less effective than LABA and LTR. • Side effects: • gastrointestinal symptoms • cardiac arrhythmias • seizures, and even death • Drug interaction

  48. Anti-IgE • Omalizumab (Xolair) indication: • Uncontrolled severe allergic asthma on high dose ICS and other controllers. • Needs specialist consultation. • Side effects: • Pain and bruising at injection site and very rarely anaphylaxis (0.1%).

  49. Oral glucocorticosteroids • Long-term oral glucocorticosteroid therapy may be required for uncontrolled asthma despite maximum standard therapy. • It is limited by the risk of significant adverse effects. • Side effects: • Osteoporosis, hypertension, diabetes, adrenal insufficiency, obesity, cataracts, glaucoma, skin thinning, and muscle weakness. Withdrawal can elicit adrenal failure. • In patients prescribed long-term systemic glucocorticosteroids, prophylactic treatment for osteoporosis should be considered.

  50. Reliever Medications • Short-acting inhaled B2-agonists • Anticholinergics • Theophylline

More Related